Bio-Techne reports Q4 adjusted EPS 55c, consensus 55c

Reports Q4 revenue $301.32M, consensus $307.25M. “We finished fiscal 2023 largely in-line with our expectations, as the Bio-Techne team continued to successfully grow on top of high year-over-year comparisons and navigate dynamic end market conditions that included a lower biotech funding environment and soft macro-economic conditions in China,” said Chuck Kummeth, president and CEO of Bio-Techne. “We delivered these results with a continued focus on operational efficiencies, leading to an adjusted operating margin of 37.1%.”